Mesoblast Has Major Hurdles (NASDAQ:MESO)

DarkGel Late in November, Mesoblast (NASDAQ:MESO) filed for orphan drug designation and rare pediatric disease designation for its allogeneic cell therapy Revascor® (rexlemestrocel-L) in the treatment of the congenital heart disease hypoplastic left heart syndrome (HLHS). This is its second cell therapy program, the first being remestemcel-L targeting pediatric acute graft versus host disease (aGVHD),…

Read More